Eagle Global Scientific, LLC, Atlanta, GA (Ms Reeves, Dr Carlson, and Ms Fox).
Division of Birth Defects and Infant Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA (Ms Neelam; Drs Olsen, Woodworth, Cohn, and Gilboa; and Ms Tong).
Am J Obstet Gynecol MFM. 2024 Feb;6(2):101265. doi: 10.1016/j.ajogmf.2023.101265. Epub 2023 Dec 21.
SARS-CoV-2 infection in pregnancy is associated with an increased risk of adverse birth outcomes such as preterm birth, stillbirth, and maternal and infant complications. Previous research suggests an increased risk of severe COVID-19 illness and stillbirth in pregnant people during delta variant predominance in 2021; however, those studies did not assess timing of infection during pregnancy, and few of them described COVID-19 vaccination status.
Using a large population-based cohort, this study compared pregnancy and infant outcomes and described demographic and clinical characteristics of pregnant people with SARS-CoV-2 infection prior to and during the delta variant period.
This retrospective cohort analysis included persons with confirmed SARS-CoV-2 infection in pregnancy from 6 US jurisdictions reporting to the Surveillance for Emerging Threats to Pregnant People and Infants Network. Data were collected through case reports of polymerase chain reaction-positive pregnant persons and linkages to birth certificates, fetal death records, and immunization records. We described clinical characteristics and compared frequency of spontaneous abortion (<20 weeks of gestation), stillbirth (≥20 weeks), preterm birth (<37 weeks), small for gestational age, and term infant neonatal intensive care unit admission between the time periods of pre-delta and delta variant predominance. Study time periods were determined by when variants constituted more than 50% of sequences isolated according to regional SARS-CoV-2 genomic surveillance data, with time periods defined for pre-delta (March 3, 2020-June 25, 2021) and Delta (June 26, 2021-December 25, 2021). Adjusted prevalence ratios were estimated for each outcome measure using Poisson regression and were adjusted for continuous maternal age, race and ethnicity, and insurance status at delivery.
Among 57,563 pregnancy outcomes, 57,188 (99.3%) were liveborn infants, 65 (0.1%) were spontaneous abortions, and 310 (0.5%) were stillbirths. Most pregnant persons were unvaccinated at the time of SARS-CoV-2 infection, with a higher proportion in pre-delta (99.4%) than in the delta period (78.4%). Of those with infections during delta and who were previously vaccinated, the timing from last vaccination to infection was a median of 183 days. Compared to pre-delta, infections during delta were associated with a higher frequency of stillbirths (0.7% vs 0.4%; adjusted prevalence ratio, 1.55; 95% confidence interval, 1.14-2.09) and preterm births (12.8% vs 11.9%; adjusted prevalence ratio, 1.14; 95% confidence interval, 1.07-1.20). The delta period was associated with a lower frequency of neonatal intensive care unit admission (adjusted prevalence ratio, 0.74; 95% confidence interval, 0.67-0.82) than in the pre-delta period. During the delta period, infection during the third trimester was associated with a higher frequency of preterm birth (adjusted prevalence ratio, 1.41; 95% confidence interval, 1.28-1.56) and neonatal intensive care unit admission (adjusted prevalence ratio, 1.21; 95% confidence interval, 1.01-1.45) compared to the first and second trimester combined.
In this US-based cohort of persons with SARS-CoV-2 infection in pregnancy, the majority were unvaccinated, and frequencies of stillbirth and preterm birth were higher during the delta variant predominance period than in the pre-delta period. During the delta period, frequency of preterm birth and neonatal intensive care unit admission was higher among infections occurring in the third trimester vs those earlier in pregnancy. These findings demonstrate population-level increases of adverse fetal and infant outcomes, specifically in the presence of a COVID-19 variant with more severe presentation.
SARS-CoV-2 感染与早产、死产和母婴并发症等不良出生结局的风险增加有关。先前的研究表明,在 2021 年 delta 变体占主导地位期间,感染 delta 变体的孕妇患严重 COVID-19 疾病和死产的风险增加;然而,这些研究没有评估怀孕期间感染的时间,而且很少有研究描述 COVID-19 疫苗接种状况。
本研究使用大型基于人群的队列,比较了妊娠和婴儿结局,并描述了 delta 变体流行之前和期间感染 SARS-CoV-2 的孕妇的人口统计学和临床特征。
这项回顾性队列分析包括来自 6 个向监测孕妇和婴儿面临的新兴威胁网络报告的美国司法管辖区的确诊 SARS-CoV-2 感染孕妇。数据通过聚合酶链反应阳性孕妇的病例报告和与出生证明、胎儿死亡记录和免疫记录的链接收集。我们描述了临床特征,并比较了 delta 变体占主导地位之前和之后的时间内自发性流产(<20 周妊娠)、死产(≥20 周)、早产(<37 周)、小于胎龄和足月婴儿新生儿重症监护病房入院的频率。研究时间根据区域 SARS-CoV-2 基因组监测数据确定的变体构成超过 50%的序列的时间来确定,分为 delta 变体之前(2020 年 3 月 3 日至 2021 年 6 月 25 日)和 delta 变体(2021 年 6 月 26 日至 2021 年 12 月 25 日)。使用泊松回归估计每个结局测量的调整后患病率比,并根据连续的产妇年龄、种族和民族以及分娩时的保险状况进行调整。
在 57563 例妊娠结局中,57188 例(99.3%)为活产婴儿,65 例(0.1%)为自发性流产,310 例(0.5%)为死产。大多数孕妇在感染 SARS-CoV-2 时未接种疫苗,在 delta 之前(99.4%)比 delta 期间(78.4%)更高。在 delta 期间感染且之前接种过疫苗的人中,最后一次接种疫苗到感染的时间中位数为 183 天。与 delta 之前相比,delta 期间的感染与死产(0.7% vs 0.4%;调整后患病率比,1.55;95%置信区间,1.14-2.09)和早产(12.8% vs 11.9%;调整后患病率比,1.14;95%置信区间,1.07-1.20)的频率更高。与 delta 之前相比,delta 期间的新生儿重症监护病房入院率(调整后患病率比,0.74;95%置信区间,0.67-0.82)较低。在 delta 期间,与第一和第二孕期相比,第三孕期的感染与早产(调整后患病率比,1.41;95%置信区间,1.28-1.56)和新生儿重症监护病房入院(调整后患病率比,1.21;95%置信区间,1.01-1.45)的频率更高。
在这项基于美国的 SARS-CoV-2 感染孕妇队列中,大多数孕妇未接种疫苗,在 delta 变体占主导地位期间,死产和早产的频率高于 delta 之前期间。在 delta 期间,与妊娠早期相比,第三孕期感染与早产和新生儿重症监护病房入院的频率更高。这些发现表明,在 COVID-19 变体表现更严重的情况下,人群中不良胎儿和婴儿结局的发生率增加。